Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. From Wikipedia
The investment arm of Novo Nordisk doubled its 2024 income to €8 billion, driven by obesity drug dividends, while focusing on Asian expansion to counter challenges.
